CLDX Celldex Therapeutics: Forward P/S Multiple
Celldex Therapeutics (CLDX) is facing a liquidity shortage due to R&D expenditures, while Anthony Maralucchi pragmatically allocates resources toward developing antibodies for inflammation therapy. The forward P/S ratio helps assess the adequacy of the scalability premium, where the 13951.10 level captures current values. Supply stability relies on external contractors, as clearly evidenced by the price action on this chart.
Celldex Corp (CLDX) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
- financial results and valuation multiples details:
CLDX - Final Profit|Future Profit Celldex Therapeutics|CLDX - Market Price to Net Income Ratio|Forward P/E Multiple Celldex|CLDX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Celldex Corp|CLDX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Celldex Therapeutics|CLDX - Earnings per share for the trailing year|Quarterly EPS earnings growth celldex.com|CLDX - Earnings growth in current year|Net earnings per share growth forecast for next year Celldex Therapeutics
- revenue and sales details:
Fundamental company valuation:Celldex Therapeutics, Inc. CLDX
The forward P/S ratio compares current market capitalization with projected revenue, determining the premium for expected sales growth. This metric allows an investor to filter out market volatility and assess the fairness of the asset's value relative to its commercial potential. By analyzing the expected P/S ratio, one can identify the risk of overpaying for Celldex Therapeutics (CLDX) shares. This is critical given that the company's valuation depends on the outcomes of barzolvolimab clinical trials and the rate of R&D cash burn.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA Corp (ADMA) - Forward Price-to-Revenue Multiple|PTGX: Forward P/S Multiple|Market Cap to Future Revenue Ratio immunovant.com (IMVT)|Price-to-Projected Revenue Ratio Kiniksa|Price-to-Projected Revenue Ratio GRFS|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio AUPH (Aurinia Corp)|Forward P/S Multiple BCRX (BioCryst)|VERA: Market Cap to Projected Revenue|Dianthus Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pharvaris NV|ABCL (AbCellera Biologics Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue TRML|Forward Price-to-Revenue Multiple PGEN|PHAR: Forward Price to Sales|Forward Price-to-Revenue Multiple NKTR (Nektar Therapeutics Inc.)|Price to Expected Revenue Ratio UPB|Forward P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Forward Price to Sales IMNM|Gossamer Bio, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio kalvista.com|Septerna (SEPN) - Price-to-Projected Revenue Ratio|Pieris Pharma - Forward Price to Sales|SVRA (Savara Corp) - Forward P/S Multiple|Forward P/S Multiple Rigel Corp|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS: Future Price to Revenue|Forward P/S Multiple ENGN (enGene)|RAPT Therapeutics Inc. (RAPT) - Market Cap to Future Revenue Ratio|JBIO: Forward Price-to-Revenue Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|TLSA: Price to Expected Revenue Ratio|CABA (Cabaletta Bio) - Forward P/S Multiple|Ventyx Biosciences Inc. (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|Forward Price-to-Revenue Multiple Avalo Therapeutics Inc AVTX|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|Market Cap to Expected Sales Ratio agenusbio.com (AGEN)|Climb Bio - Forward P/S Multiple|Zura Bio Ltd (ZURA) - Forward Price-to-Revenue Multiple|aTyr (ATYR) - Price-to-Projected Revenue Ratio|ADAG (Adagene Inc.) - Price-to-Projected Revenue Ratio|IMA (ImageneBio) - Forward P/S Multiple|Market Cap to Projected Revenue STTK (Shattuck Therapeutics)|Forward Price-to-Revenue Multiple EQ (Equillium, Inc.)|connectbiopharm.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Immunic IMUX|ATRA (Atara Biotherapeutics, Inc.) - Future Price to Revenue|InflaRx GmbH - Forward P/S Multiple|Forward Price to Sales XFOR (x4pharma.com)|ACET: Forward P/S Multiple|Celularity (CELU) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INmune Bio Corp|BRNS: Forward Price to Sales|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|Forward Price-to-Revenue Multiple sabbiotherapeutics.com SABS|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Forward P/S Multiple Enlivex Therapeutics Ltd ENLV|QTTB: Forward Price-to-Revenue Multiple|Forward Price to Sales GOVX (GeoVax Corp)|EDSA: Forward P/S Multiple|IBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Forward Price-to-Revenue Multiple XTL Biopharmaceuticals Ltd (XTLB)|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple AIM ImmunoTech, Inc. AIM|ADTX - Price-to-Projected Revenue Ratio|GRI (GRI Bio Inc) - Market Cap to Projected Revenue|XRTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Vyome Therapeutics (HIND)|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward P/S Multiple SCNI|CALI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|Allakos Inc - Price-to-Projected Revenue Ratio|HOOK - Price-to-Projected Revenue Ratio|IGMS: Price-to-Projected Revenue Ratio|ITOS: Forward P/S Multiple|Market Cap to Projected Revenue OCEA|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Third Harmonic Bio Inc THRD
